Document is current
Any future updates will be listed below
-
Authors
Kaas, Mathias https://orcid.org/0000-0002-4122-4401
Dinesen, Sarah Broholt
Ahlgreen, Ole https://orcid.org/0009-0004-4844-9058
Madsen, Peder
Mølgaard, Simon
Dalby, Anders https://orcid.org/0000-0002-2255-1335
Gustafsen, Camilla
Olsen, Ditte
Duan, Jinjie https://orcid.org/0000-0002-3402-302X
Vilstrup, Joachim
Lende, Jonas https://orcid.org/0009-0009-3620-7680
Nordestgaard, Sanne
Zayats, Tetyana
Knappskog, Per Morten
Johansson, Stefan https://orcid.org/0000-0002-2298-7008
Neckelmann, Gesche
Franke, Barbara https://orcid.org/0000-0003-4375-6572
Thirup, Søren https://orcid.org/0000-0002-0061-7137
Børglum, Anders https://orcid.org/0000-0001-8627-7219
Reif, Andreas https://orcid.org/0000-0002-0992-634X
Vægter, Christian https://orcid.org/0000-0001-6573-146X
Demontis, Ditte https://orcid.org/0000-0001-9124-2766
Haavik, Jan https://orcid.org/0000-0001-7865-2808
Glerup, Simon https://orcid.org/0000-0002-9686-8124
Skeldal, Sune
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden
Lundbeckfonden
Det Frie Forskningsråd (DFF 4183-00604)
- License Information
-
More Information
Article History
Received: 24 July 2024
Revised: 20 July 2025
Accepted: 5 September 2025
First Online: 18 September 2025
Competing interests
: MK, SM, AD and SG are shareholders in Teitur Trophics, a biotechnology company involved in developing SorCS2 derived peptides. SN is an employee of Teitur Trophics. BF has received educational speaking fees and travel support from Medice. AD has received speaker fee from Lundbeck. JH has received lecture honoraria as part of continuing medical education programs sponsored by Medice.
